HEIDELBERG, Germany and GEMBLOUX, Belgium and SHANGHAI, China, July 22, 2024 /PRNewswire/ — Full-Life Technologies, a fully integrated global radiation oncology company, today announced the appointment of Ted Myles to Full-Life Board of DirectorsMr. Myles will serve as Chairman of the Audit Committee and as a member of the Remuneration Committee of the Board of Directors.

“We are pleased to welcome Ted to Full-Life’s Board of Directors at this important time in the company’s development. Ted has extensive experience guiding biotechnology companies through all stages of clinical development and commercialization and has been very successful in helping these companies access the capital they need to advance their programs to benefit patients in need,” said Lanny Zon, Co-founder, Chairman, and CEO of Full-Life. “We welcome Ted to the board as we enter this important phase in Full-Life’s evolution, marked by significant progress in both our pipeline and our manufacturing facilities. Our leadership program, ²²⁵Ac-FL-020 has received Investigational New Drug (IND) approval from the U.S. Food and Drug Administration (FDA) for a clinical trial in metastatic castration-resistant prostate cancer (mCRPC) and has been granted Fast Track Designation to accelerate the clinical development pathway. Our manufacturing facility in Belgium has received nuclear license, allowing us to commence radioactive production once construction of the facility is complete. We also recently closed a $571.5 million out-licensing deal with SK Biopharmaceuticals, which will further develop our FL-091 radiopharmaceutical compound into an innovative anti-cancer treatment for global markets. These achievements underscore our commitment to bringing life-saving therapies to patients around the world. I am excited to have Ted join our Board of Directors as we continue to execute on our plan and move Full-Life forward.”

“I am pleased to join Full-Life’s Board of Directors as the company is poised to initiate the global Phase I clinical trial for its lead program ²²⁵Ac-FL-020. I look forward to working with the team and sharing my experience and expertise to successfully deliver promising therapies to the many patients awaiting new radiotherapies,” said Mr. Myles.

Mr. Myles is an accomplished biotechnologist with three decades of deep financial and operational experience in biotechnology and pharmaceuticals. He currently serves as Chief Operating Officer and Chief Financial Officer of Scholar Rock, a late-stage biotechnology company focused on developing innovative treatments for spinal muscular atrophy, cardiometabolic disorders and other serious diseases in which protein growth factors play a fundamental role. Mr. Myles has raised over half a billion dollars in venture capital to support Scholar Rock’s rich pipeline during his tenure at the company. Prior to joining Scholar Rock, Mr. Myles was COO & CFO of AMAG Pharmaceuticals, a commercial-stage pharmaceutical company acquired by Covis Pharmaceuticals. Before that, Mr. Myles was COO & CFO of Ocata Therapeutics, a cell therapy company acquired by Astellas. Earlier in his career, Mr. Myles was an investment banker in the healthcare group of SG Cowen Securities. Mr. Myles holds an MBA from the Olin School of Business, Washington University in St. Louis and a BSBA from the University of Hartford.

About Full-Life Technologies

Full-Life Technologies (“Full-Life”) is a fully integrated global radiation oncology company with operations in Belgium, Germany and China. We aim to own the entire value chain for radiopharmaceutical research and development, manufacturing and commercialization to deliver clinical impact for patients. The company strives to address fundamental challenges affecting radiopharmaceuticals today by conducting groundbreaking innovative research that will shape the treatments of tomorrow. We consist of a team of fast-growing entrepreneurs and experienced scientists with a proven history of success in the life sciences, in addition to radioisotope research and clinical development.